阿斯利康(AZN)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

AZN 阿斯利康

盘后交易 11-18 17:17:59 EST

63.39

+0.16

+0.25%

盘后63.37

-0.02-0.03%

17:13 EST

最高63.65	最低62.75	成交量794.52万
今开63.00	昨收63.23	日振幅1.42%
总市值1,965亿	流通市值1,959亿	总股本31.01亿
成交额5.02亿	换手率0.26%	流通股本30.90亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"AZN","market":"US","secType":"STK","nameCN":"阿斯利康","latestPrice":63.39,"timestamp":1731963600000,"preClose":63.23,"halted":0,"volume":7945203,"hourTrading":{"tag":"盘后","latestPrice":63.37,"preClose":63.39,"latestTime":"17:13 EST","volume":901146,"amount":57123888.24942,"timestamp":1731967980949},"delay":0,"floatShares":3089632141,"shares":3100574690,"eps":2.075055,"marketStatus":"盘后交易","marketStatusCode":4,"change":0.16,"latestTime":"11-18 17:17:59 EST","open":63,"high":63.65,"low":62.75,"amount":502207033.413708,"amplitude":0.014234,"askPrice":64,"askSize":26,"bidPrice":63,"bidSize":232,"shortable":3,"etf":0,"ttmEps":2.075055,"exchange":"NASDAQ","tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1731978000000},"adr":1,"listingDate":737179200000,"adjPreClose":63.23,"adrRate":0.5,"dividendRate":0.023426,"preHourTrading":{"tag":"盘前","latestPrice":62.99,"preClose":63.23,"latestTime":"09:29 EST","volume":322403,"amount":20278353.331799,"timestamp":1731940199999},"postHourTrading":{"tag":"盘后","latestPrice":63.37,"preClose":63.39,"latestTime":"17:13 EST","volume":901146,"amount":57123888.24942,"timestamp":1731967980949},"volumeRatio":0.922579,"optionData":{"bulkOrders":[{"symbol":"AZN","call":false,"expireDate":1732251600000,"strike":"69.0","timestamp":1731945007820,"price":6,"volume":4395,"amount":2637000,"type":"*"},{"symbol":"AZN","call":false,"expireDate":1732251600000,"strike":"69.0","timestamp":1731949976438,"price":6,"volume":4381,"amount":2628600,"type":"+"}]},"impliedVol":0.2852,"impliedVolPercentile":0.8526},"requestUrl":"/m/hq/s/AZN","defaultTab":"news","newsList":[{"id":"2484625898","title":"巴克莱分析师：2025年制药行业前景更具挑战","url":"https://stock-news.laohu8.com/highlight/detail?id=2484625898","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484625898?lang=zh_cn&edition=full","pubTime":"2024-11-18 19:42","pubTimestamp":1731930130,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["LU0109394709.USD","LU0320765992.SGD","LU1093756168.USD","LU2456880835.USD","BK4007","AZN","LU2236285917.USD","NVO","LU1093756325.SGD","BK4532","IE00BKVL7J92.USD","BK4568","BK1574","BK1191","01477","LU1829250122.USD","BK4585","LU0154236417.USD","BK4588","LU2417539215.USD","LU0889565916.HKD","LU2462157665.USD","IE00BZ1G4Q59.USD"],"gpt_icon":0},{"id":"2483560167","title":"站在“雪崩”边缘的阿斯利康会成为下一个GSK吗？","url":"https://stock-news.laohu8.com/highlight/detail?id=2483560167","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483560167?lang=zh_cn&edition=full","pubTime":"2024-11-16 15:39","pubTimestamp":1731742740,"startTime":"0","endTime":"0","summary":"十年前中国掀起的“反腐风暴”曾让英国制药公司葛兰素史克经历一场剧变。十年后，又一家英国制药公司阿斯利康再次站上“雪崩”的边缘。　　11月15日，阿斯利康中国区总裁王磊已被拘留长达半个月。迄今为止，外界对王被调查的原因仍一无所知。　　相关律师对第一财经记者表示，阿斯利康大范围“骗保案”未针对单位进行立案，有蹊跷之处，而王磊作为阿斯利康中国区“一把手”被拘留，可能是一个开端。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/jjxw/2024-11-16/doc-incwfyam9015974.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2024-11-16/doc-incwfyam9015974.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["GSK","LU1829250122.USD","GSK.UK","BK4007","LU2236285917.USD","LU2456880835.USD","LU2462157665.USD","BK4588","LU0109394709.USD","LU0320765992.SGD","BK4568","AZN","BK4532","LU2417539215.USD","LU0889565916.HKD","BK4585"],"gpt_icon":0},{"id":"2483604388","title":"前三季度阿斯利康中国区营收超50亿美元 公司回应近期调查风波：还不了解细节，将全力配合","url":"https://stock-news.laohu8.com/highlight/detail?id=2483604388","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483604388?lang=zh_cn&edition=full","pubTime":"2024-11-14 23:42","pubTimestamp":1731598970,"startTime":"0","endTime":"0","summary":"当地时间11月12日，阿斯利康公布了2024年三季报。在同日举行的业绩交流会上，阿斯利康管理层回应了公司近期在中国市场遭遇的调查风波。其中，作为营收大头，今年前三季度，阿斯利康肿瘤业务收入为160.09亿美元，同比增长22%，占总药品营收比重为41%。据了解，基于三季报业绩，阿斯利康近日再次上调了全年业绩增长预期。阿斯利康在第三季度财报中确认，其尚未收到任何针对公司本身的调查通知，但如果被要求，将会全力配合。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241114234355abc1816e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241114234355abc1816e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AZN"],"gpt_icon":0},{"id":"2483981858","title":"阿斯利康（AZN.US）：公司宣布在美国投资35亿美元用于制造和研发，并承诺继续在中国投资","url":"https://stock-news.laohu8.com/highlight/detail?id=2483981858","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483981858?lang=zh_cn&edition=full","pubTime":"2024-11-14 09:35","pubTimestamp":1731548100,"startTime":"0","endTime":"0","summary":"来源：Gangtise投研\n阿斯利康（AZN.US) 第三季度业绩强劲，总收入增长21%，核心每股收益增长27%。公司上调全年指导，预计总收入和核心EPS将以高双位数百分比增长。新兴市场表现突出，增长30%。公司宣布在美国投资35亿美元用于制造和研发，并承诺继续在中国投资。研发方面取得进展，多项高价值III期结果公布。公司对2025年增长前景充满信心，预计将继续实现强劲的盈利增长，并有望在2030年实现800亿美元的总收入。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/us/2024-11-14/doc-incvyuyw1529998.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/us/2024-11-14/doc-incvyuyw1529998.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4568","BK4007","LU2236285917.USD","BK4585","AZN","LU0889565916.HKD","BK4588","LU2462157665.USD","LU0320765992.SGD","LU1829250122.USD","LU0109394709.USD","LU2417539215.USD","LU2456880835.USD"],"gpt_icon":0},{"id":"2483629358","title":"医药早参｜阿斯利康撤回Trop2 ADC非鳞状NSCLC上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2483629358","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483629358?lang=zh_cn&edition=full","pubTime":"2024-11-14 08:22","pubTimestamp":1731543747,"startTime":"0","endTime":"0","summary":"每经记者：陈星每经编辑：魏官红｜ 2024年11月14日 星期四 ｜NO.1 阿斯利康撤回Trop2 ADC非鳞状NSCLC的上市申请阿斯利康宣布撤回此前基于TROPION-Lung01三期临床数据递交的治疗非鳞状NSCLC的上市申请，转而递交复发性或转移性EGFR突变NSCLC的后线治疗上市申请。这一上市申请的策略调整是在FDA反馈的基础上做出的。NO.4 卡尔史托斯首批国产内镜影像产品获批上市全球医疗技术公司卡尔史托斯宣布其首批国产内窥镜影像产品已正式获得医疗器械注册证。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241114082335abbef158&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241114082335abbef158&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1829250122.USD","LU2236285917.USD","LU0889565916.HKD","LU2456880835.USD","LU0109394709.USD","BK4080","BK4231","LU2462157665.USD","BK4007","LU2417539215.USD","BK4585","AZN","LU0320765992.SGD","BK4568","BK4588","ADC"],"gpt_icon":0},{"id":"2483886943","title":"阿斯利康（AZN.US）：第三季度业绩强劲，全年指导上调，新兴市场增长突出，研发取得进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2483886943","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483886943?lang=zh_cn&edition=full","pubTime":"2024-11-14 06:40","pubTimestamp":1731537600,"startTime":"0","endTime":"0","summary":"01. 阿斯利康（AZN.US) 第三季度业绩强劲，总收入增长21%，核心每股收益增长27%。公司上调全年指导，预计总收入和核心EPS将以高双位数百分比增长。新兴市场表现突出，增长30%。公司宣布在美国投资35亿美元用于制造和研发，并承诺继续在中国投资。研发方面取得进展，多项高价值III期结果公布。公司对2025年增长前景充满信心，预计将继续实现强劲的盈利增长，并有望在2030年实现800亿美元的总收入。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2024-11-14/doc-incvyqsy1613175.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2024-11-14/doc-incvyqsy1613175.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU2456880835.USD","BK4588","BK4585","BK4007","LU0320765992.SGD","LU0889565916.HKD","LU2236285917.USD","AZN","LU2417539215.USD","LU1829250122.USD","BK4568","LU0109394709.USD","LU2462157665.USD"],"gpt_icon":0},{"id":"2483022966","title":"阿斯利康CEO回应中国区收入增长15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2483022966","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483022966?lang=zh_cn&edition=full","pubTime":"2024-11-13 16:27","pubTimestamp":1731486420,"startTime":"0","endTime":"0","summary":"#阿斯利康CEO称将在中国长期发展#正处于多事之秋的阿斯利康，近日公布了2024年三季报业绩。2024年前三季度，阿斯利康全球总营收391.82亿美元、同比增长19%，其中中国区实现收入50.49亿美元，同比增长15%，中国区收入也再次反超默沙东中国区收入，后者收入是46.06亿美元。在阿斯利康三季报未披露前，阿斯利康全球执行副总裁、国际业务主席及中国总裁王磊被调查的消息震惊市场。阿斯利康在三季报中已确认王磊被拘留。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/jjxw/2024-11-13/doc-incvxhxn5492186.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2024-11-13/doc-incvxhxn5492186.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["AZN","BK4585","LU0109394709.USD","LU2417539215.USD","LU0889565916.HKD","BK4588","LU0320765992.SGD","LU1829250122.USD","BK4007","LU2462157665.USD","BK4568","LU2236285917.USD","LU2456880835.USD"],"gpt_icon":0},{"id":"2483027846","title":"阿斯利康中国市场收入第一，全球高管回应王磊被调查事件影响","url":"https://stock-news.laohu8.com/highlight/detail?id=2483027846","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483027846?lang=zh_cn&edition=full","pubTime":"2024-11-13 16:25","pubTimestamp":1731486342,"startTime":"0","endTime":"0","summary":"尽管前三季度阿斯利康在中国市场的表现引人注目，但10月30日晚，阿斯利康宣布王磊配合调查的消息在医药界引起了广泛关注。在2024年上半年，阿斯利康在中国市场的收入达到33.78亿美元，同比增长15%，占其全球总营收的13.19%，这一比例在众多跨国制药企业中位居榜首。尽管如此，阿斯利康在中国的战略布局似乎并未受到影响。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241113163548a23339ad&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241113163548a23339ad&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","LU2462157665.USD","BK4585","LU0320765992.SGD","LU0889565916.HKD","LU2236285917.USD","LU2417539215.USD","BK4568","YINN","BK4588","AZN","LU2456880835.USD","LU1829250122.USD","LU0109394709.USD"],"gpt_icon":0},{"id":"2483226910","title":"阿斯利康全球CEO回应中国业务收入两位数增长原因","url":"https://stock-news.laohu8.com/highlight/detail?id=2483226910","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483226910?lang=zh_cn&edition=full","pubTime":"2024-11-13 16:22","pubTimestamp":1731486171,"startTime":"0","endTime":"0","summary":"正处于多事之秋的阿斯利康，近日公布了2024年三季报业绩。据显示，2024年前三季度，阿斯利康全球总营收391.82亿美元、同比增长19%，其中中国区实现收入50.49亿美元，同比增长15%，中国区收入也再次反超默沙东中国区收入，后者收入是46.06亿美元。在阿斯利康三季报未披露前，阿斯利康全球执行副总裁、国际业务主席及中国总裁王磊被调查的消息震惊市场。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202411133238478459.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202411133238478459.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2236285917.USD","LU2417539215.USD","BK4007","LU0109394709.USD","LU2462157665.USD","LU2456880835.USD","BK4588","LU0320765992.SGD","BK4585","BK4568","LU0889565916.HKD","AZN","LU1829250122.USD"],"gpt_icon":0},{"id":"2483420030","title":"阿斯利康(AZN.US)潜在重磅ADC疗法向FDA递交上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2483420030","media":"智通财经","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483420030?lang=zh_cn&edition=full","pubTime":"2024-11-13 14:37","pubTimestamp":1731479821,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，11月13日，阿斯利康和第一三共宣布，根据美国FDA的反馈，两家公司已为其联合开发的Trop2靶向抗体偶联药物datopotamab deruxtecan递交生物制品许可申请，寻求该疗法获加速批准，用以治疗携带表皮生长因子受体突变肿瘤的局部晚期或转移性非小细胞肺癌成年患者，这些患者之前曾接受过全身性治疗。同时，两家公司自愿撤回之前向FDA所递交该疗法用以治疗晚期或转移性非鳞状NSCLC患者的BLA。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1210290.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0320765992.SGD","BK4080","BK4007","LU0109394709.USD","LU2462157665.USD","LU0889565916.HKD","LU2417539215.USD","BK4568","ADC","BK4588","BK4231","LU1829250122.USD","LU2236285917.USD","BK4585","AZN","LU2456880835.USD"],"gpt_icon":0},{"id":"2483311041","title":"达嘉维康：公司主要客户为国际药企或国内知名药企","url":"https://stock-news.laohu8.com/highlight/detail?id=2483311041","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483311041?lang=zh_cn&edition=full","pubTime":"2024-11-13 13:49","pubTimestamp":1731476964,"startTime":"0","endTime":"0","summary":"每经AI快讯，有投资者在投资者互动平台提问：董秘你好！请问公司和医药巨头阿斯利康有合作吗？达嘉维康（301126.SZ）11月13日在投资者互动平台表示，公司主要客户为国际药企或国内知名药企。作为国内最早一批进入医药分销行业的公司，凭借专业化的服务能力，公司成为辉瑞、拜耳、阿斯利康、葛兰素史克、恒瑞、康方、正大天晴、强生、百时美施贵宝等众多知名国内外药企的合格供应商。公司的业务合作与经营信息均以公开披露的公告文件为准。(记者 蔡鼎)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241113135056abbc21bf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241113135056abbc21bf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","LU2417539215.USD","LU0889565916.HKD","LU0109394709.USD","LU2462157665.USD","LU2456880835.USD","BK4007","LU0320765992.SGD","BK4568","LU1829250122.USD","AZN","LU2236285917.USD","BK4585"],"gpt_icon":0},{"id":"2483201725","title":"跨国巨头高管被拘新进展！阿斯利康全球CEO苏博科：不了解任何调查细节，目前掌握信息有限","url":"https://stock-news.laohu8.com/highlight/detail?id=2483201725","media":"时代财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483201725?lang=zh_cn&edition=full","pubTime":"2024-11-13 11:54","pubTimestamp":1731470087,"startTime":"0","endTime":"0","summary":"当地时间11月12日，阿斯利康（AstraZeneca）全球CEO苏博科（PascalSoriot）首次对外公开回应该公司中国区总裁王磊被拘留事件。苏博科在这一面向投资者和分析师的线上会上表示：“王磊正在与他的律师讨论，公司不掌握关于案件的新信息。”“关于中国的事情，我们真的很重视。我今天已经说过几次了，但我想再说一遍。”苏博科强调道。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202411133238293150.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1829250122.USD","LU2456880835.USD","LU2236285917.USD","AZN","LU2417539215.USD","LU0889565916.HKD","LU0109394709.USD","LU2462157665.USD","BK4568","BRCD","BK4007","BK4585","BK4588","LU0320765992.SGD"],"gpt_icon":0},{"id":"2483015432","title":"阿斯利康：35亿美元投资，上调业绩指引，递交BLA","url":"https://stock-news.laohu8.com/highlight/detail?id=2483015432","media":"生物药大时代","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483015432?lang=zh_cn&edition=full","pubTime":"2024-11-13 10:35","pubTimestamp":1731465305,"startTime":"0","endTime":"0","summary":"02在美投资35亿美元阿斯利康宣布将在美国投资35亿美元，重点是在2026年底之前扩大公司的研究和生产规模。美国是阿斯利康最大的市场，占其总收入的 44%。目前阿斯利康拥有约 17,800 名员工，分布在12个州的17个研发、生产和商业基地。同时，两家公司自愿撤回之前向FDA所递交该疗法用以治疗晚期或转移性非鳞状NSCLC患者的BLA。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241113103624abbbad88&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241113103624abbbad88&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2417539215.USD","LU2236285917.USD","BK4007","AZN","BK4585","LU2456880835.USD","BK4588","LU0320765992.SGD","BK4568","LU1829250122.USD","LU2462157665.USD","LU0889565916.HKD","LU0109394709.USD"],"gpt_icon":0},{"id":"2483091287","title":"阿斯利康(AZN.US)和默沙东(MRK.US)联合公布KOMET临床3期试验的积极顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2483091287","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483091287?lang=zh_cn&edition=full","pubTime":"2024-11-13 09:13","pubTimestamp":1731460430,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，今日，阿斯利康和默沙东联合公布KOMET临床3期试验的积极顶线结果。分析显示，两家公司共同开发的Koselugo用于治疗患有症状性、不可手术丛状神经纤维瘤的1型神经纤维瘤病成人患者时，能够使患者的肿瘤体积显著缩小，达成试验主要终点。NF1是一种罕见，不可治愈的遗传性疾病。该基因突变可扰乱RAS/MAPK信号通路，进而导致肿瘤的生长。Koselugo能够选择性地抑制MEK1和MEK2，从而让失调的信号通路恢复正常，进而缓解NF1患者的病情。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1210179.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE0009355771.USD","LU1934455277.USD","IE00BBT3K403.USD","LU0289739699.SGD","LU2236285917.USD","LU0106261372.USD","IE00BJT1NW94.SGD","BK4550","LU1116320901.HKD","LU1057294990.SGD","IE00BSNM7G36.USD","LU1829250122.USD","BK4533","LU2417539215.USD","LU0320765489.SGD","MRK","LU1023059063.AUD","IE00BN8TJ469.HKD","LU0122379950.USD","IE00B2B36J28.USD","LU1291159041.SGD","LU0965508806.USD","LU1941712264.USD","LU1093756325.SGD","LU0320765992.SGD","LU0058720904.USD","LU0266013472.USD","BK4534","IE00BLSP4239.USD","LU0203347892.USD","AZN","LU0965509101.SGD","LU0985320562.USD","BK4568","LU0238689110.USD","LU1061106388.HKD","LU1093756168.USD","LU1934455194.USD","LU2462157665.USD","IE000M9KFDE8.USD","LU0861579265.USD","LU1037948541.HKD","BK4516","BK4585","BK4559","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","IE00BLSP4452.SGD","LU0109394709.USD"],"gpt_icon":0},{"id":"2483966570","title":"阿斯利康全球CEO首次回应中国高管被拘留：王磊正与律师讨论","url":"https://stock-news.laohu8.com/highlight/detail?id=2483966570","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483966570?lang=zh_cn&edition=full","pubTime":"2024-11-13 08:33","pubTimestamp":1731458014,"startTime":"0","endTime":"0","summary":"当地时间11月12日，阿斯利康全球CEO苏博科首次对外公开回应该公司中国区总裁王磊被拘留事件。苏博科是在阿斯利康第三季度财报发布后作出上述回应的。不过，他否认阿斯利康总部对合规缺乏监督。10月30日晚，阿斯利康发布公告称，该公司中国区总裁王磊正在接受调查。11月6日，阿斯利康临时召开投资人会议，披露王磊“已被拘留”的最新进展，不过阿斯利康强调，目前中国有关部门仅对公司高管个人进行调查，并不涉及公司业务。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241113083450a231cd04&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241113083450a231cd04&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","BK4588","LU2456880835.USD","LU2417539215.USD","BK4007","LU2462157665.USD","AZN","BK4568","LU0320765992.SGD","LU0889565916.HKD","LU1829250122.USD","LU2236285917.USD","LU0109394709.USD"],"gpt_icon":0},{"id":"2483206098","title":"阿斯利康CEO：不了解中国高管被调查细节 将继续在华投资","url":"https://stock-news.laohu8.com/highlight/detail?id=2483206098","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483206098?lang=zh_cn&edition=full","pubTime":"2024-11-13 07:45","pubTimestamp":1731455136,"startTime":"0","endTime":"0","summary":"【阿斯利康CEO：不了解中国高管被调查细节 将继续在华投资】“关于中国的事情，我们真的很重视。我今天已经说过几次了，但我想再说一遍。”英国时间11月12日，阿斯利康CEO苏博科在一场面向投资者和分析师的线上会上强调道。苏博科表示，公司并不了解任何调查的细节，如果被要求，将像过去一样充分配合。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://stock.eastmoney.com/a/202411133237667575.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://stock.eastmoney.com/a/202411133237667575.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4585","BK4588","LU2456880835.USD","LU2417539215.USD","BK4007","LU2462157665.USD","AZN","BK4568","LU0320765992.SGD","LU0889565916.HKD","LU1829250122.USD","LU2236285917.USD","LU0109394709.USD"],"gpt_icon":0},{"id":"2483406721","title":"阿斯利康CEO：不了解中国高管被调查细节，将继续在华投资","url":"https://stock-news.laohu8.com/highlight/detail?id=2483406721","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483406721?lang=zh_cn&edition=full","pubTime":"2024-11-13 07:43","pubTimestamp":1731455028,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["LU1829250122.USD","LU0889565916.HKD","BK4007","AZN","LU2456880835.USD","BK4568","LU0109394709.USD","LU2417539215.USD","BK4588","BRCD","LU2236285917.USD","LU2462157665.USD","LU0320765992.SGD","BK4585"],"gpt_icon":0},{"id":"2482704449","title":"金十数据整理：每日美股市场要闻速递（11月12日 周二）","url":"https://stock-news.laohu8.com/highlight/detail?id=2482704449","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482704449?lang=zh_cn&edition=full","pubTime":"2024-11-12 21:31","pubTimestamp":1731418319,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK4588","BK4563","IE00BJT1NW94.SGD","RDSA.UK","LU0792757196.USD","AZN","BK4017","BK4127","LU0345769128.USD","CDE","LU0640476718.USD","LU0109394709.USD","IE0002141913.USD","RDS.B","SHEL","BK4592","BK4007","161631","IE00BSNM7G36.USD","LU1162221912.USD","AVNW","LU1066053197.SGD","DELL","NQGM","NVS","BK4513","IE00BVYPNW00.USD","LU0345769631.USD","BK4078","BK4533","LU2462157665.USD","IE00B3PB1722.GBP","BA","01477","BK4578","HUYA","BK4532","RDS.A","LU0320765992.SGD","IE00BGHQF631.EUR","BK4526","IE00B19Z3B42.SGD","TIGR","IE0009355771.USD","JNJ","BK4515","IE00B7SZLL34.SGD","GPRO","LU0889566641.SGD"],"gpt_icon":0},{"id":"2482021957","title":"阿斯利康：公司仍然致力于在中国开展业务","url":"https://stock-news.laohu8.com/highlight/detail?id=2482021957","media":"金吾资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482021957?lang=zh_cn&edition=full","pubTime":"2024-11-12 21:29","pubTimestamp":1731418184,"startTime":"0","endTime":"0","summary":"金吾财讯 | 据界面新闻报道，制药商阿斯利康(AZN)首席执行官苏博科（Pascal Soriot）称，公司仍然致力于在中国开展业务，既是为了患者，也是为了创新。针对该公司当地管理团队成员正在接受中国执法机构的调查，苏博科表示，对调查的细节知之甚少，该公司在中国有“强有力”的合规政策，已采取新措施来识别任何潜在的违规行为。此前，阿斯利康首席财务官Aradhana Sarin表示，目前中国区相关调查仅针对个人，不涉及公司层面。该公司也强调，如有要求，将全力配合中国的执法部门。公司将继续向中国患者提供药物，业务仍将继续进行。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241112213008abba2c86&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241112213008abba2c86&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","LU2417539215.USD","LU0889565916.HKD","LU0109394709.USD","LU2462157665.USD","LU2456880835.USD","BK4007","LU0320765992.SGD","BK4568","LU1829250122.USD","AZN","LU2236285917.USD","BK4585"],"gpt_icon":0},{"id":"2482704303","title":"阿斯利康首席执行官：仍然致力于发展中国市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2482704303","media":"界面","labels":["Company Corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482704303?lang=zh_cn&edition=full","pubTime":"2024-11-12 21:06","pubTimestamp":1731416816,"startTime":"0","endTime":"0","summary":"11月12日消息，制药商阿斯利康首席执行官苏博科（Pascal Soriot）称，公司仍然致力于在中国开展业务，既是为了患者，也是为了创新。针对该公司当地管理团队成员正在接受中国执法机构的调查，苏博科表示，对调查的细节知之甚少，该公司在中国有“强有力”的合规政策，已采取新措施来识别任何潜在的违规行为。此前，阿斯利康首席财务官Aradhana Sarin表示，目前中国区相关调查仅针对个人，不涉及公司层面。该公司也强调，如有要求，将全力配合中国的执法部门。公司将继续向中国患者提供药物，业务仍将继续进行。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241112210656abba203b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241112210656abba203b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Company Corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2417539215.USD","LU2236285917.USD","BK4007","AZN","BK4585","LU2456880835.USD","YINN","BK4588","LU0320765992.SGD","BK4568","LU1829250122.USD","LU2462157665.USD","LU0889565916.HKD","LU0109394709.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.astrazeneca.com","stockEarnings":[{"period":"1week","weight":-0.0195},{"period":"1month","weight":-0.1926},{"period":"3month","weight":-0.2509},{"period":"6month","weight":-0.1778},{"period":"1year","weight":-0.0089},{"period":"ytd","weight":-0.0612}],"compareEarnings":[{"period":"1week","weight":-0.0208},{"period":"1month","weight":0.0059},{"period":"3month","weight":0.0567},{"period":"6month","weight":0.1063},{"period":"1year","weight":0.301},{"period":"ytd","weight":0.2324}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"阿斯利康股份有限公司于1992年6月17日根据1985年《公司法》在英格兰和威尔士注册成立。该公司是在1993年将Imperial化学工业公司的制药、农化和特种化学品业务分拆时成立的。1999年，公司出售了特种化学品业务。同样在1999年，该公司与瑞典Astra公司合并。2000年，该公司将农化业务分拆，并将其与诺华公司的同类业务合并，成立了一家新的公司Syngenta AG。2007年，集团收购了位于美国的生物制剂和疫苗企业MedImmune。2021年，集团收购了位于美国的罕见病企业Alexion。","yearOnYearQuotes":[{"month":1,"riseRate":0.483871,"avgChangeRate":-0.001106},{"month":2,"riseRate":0.387097,"avgChangeRate":-0.020166},{"month":3,"riseRate":0.580645,"avgChangeRate":0.030042},{"month":4,"riseRate":0.677419,"avgChangeRate":0.03301},{"month":5,"riseRate":0.516129,"avgChangeRate":0.008567},{"month":6,"riseRate":0.46875,"avgChangeRate":0.020173},{"month":7,"riseRate":0.59375,"avgChangeRate":-0.004027},{"month":8,"riseRate":0.46875,"avgChangeRate":0.002026},{"month":9,"riseRate":0.5625,"avgChangeRate":0.002514},{"month":10,"riseRate":0.53125,"avgChangeRate":0.013465},{"month":11,"riseRate":0.5,"avgChangeRate":-0.001961},{"month":12,"riseRate":0.580645,"avgChangeRate":0.009222}],"exchange":"NASDAQ","name":"阿斯利康","nameEN":"AstraZeneca PLC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"阿斯利康(AZN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供阿斯利康(AZN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"阿斯利康,AZN,阿斯利康股票,阿斯利康股票老虎,阿斯利康股票老虎国际,阿斯利康行情,阿斯利康股票行情,阿斯利康股价,阿斯利康股市,阿斯利康股票价格,阿斯利康股票交易,阿斯利康股票购买,阿斯利康股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"阿斯利康(AZN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供阿斯利康(AZN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}